Clearline Capital LP Purchases 392,674 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Clearline Capital LP boosted its Teva stake by 55.6%, acquiring 392,674 shares to hold 1,098,786 shares valued at about $22.2 million, making TEVA its 14th largest holding.
• Teva reported stronger-than-expected quarterly results—EPS of $0.96 vs. $0.65 consensus and revenue of $4.71 billion vs. $4.36 billion—and set FY2026 guidance of 2.57–2.77 EPS, while analysts maintain a mostly positive view with a consensus price target of $37.67.
• Insiders sold a substantial amount of stock last quarter—approximately 948,499 shares worth $30.9 million—even as hedge funds and other institutions own about 54.05% of the stock.

Clearline Capital LP boosted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 55.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,098,786 shares of the company's stock after acquiring an additional 392,674 shares during the period. Teva Pharmaceutical Industries accounts for approximately 1.0% of Clearline Capital LP's portfolio, making the stock its 14th largest holding. Clearline Capital LP owned approximately 0.10% of Teva Pharmaceutical Industries worth $22,195,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Advisors Asset Management Inc. bought a new position in Teva Pharmaceutical Industries during the second quarter worth about $41,000. Cromwell Holdings LLC lifted its stake in shares of Teva Pharmaceutical Industries by 40.3% during the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company's stock valued at $44,000 after buying an additional 629 shares in the last quarter. MAI Capital Management boosted its holdings in Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company's stock worth $55,000 after buying an additional 697 shares during the period. Rothschild Investment LLC boosted its holdings in Teva Pharmaceutical Industries by 97.0% in the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company's stock worth $55,000 after buying an additional 1,348 shares during the period. Finally, JFS Wealth Advisors LLC grew its stake in Teva Pharmaceutical Industries by 257.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company's stock valued at $56,000 after buying an additional 2,000 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Down 2.6%

TEVA opened at $28.54 on Friday. The firm has a market capitalization of $32.81 billion, a P/E ratio of 23.78, a price-to-earnings-growth ratio of 9.56 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $37.35. The company has a fifty day moving average price of $32.91 and a 200-day moving average price of $26.68. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm's revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on TEVA shares. Bank of America increased their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a "buy" rating in a research report on Tuesday, December 9th. The Goldman Sachs Group lifted their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Barclays increased their price objective on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an "overweight" rating in a report on Friday, January 30th. Piper Sandler restated an "overweight" rating and issued a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. Finally, Truist Financial lifted their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a "buy" rating in a report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of "Moderate Buy" and a consensus price target of $37.67.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 7,924 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $250,953.08. Following the completion of the sale, the executive vice president owned 84,905 shares in the company, valued at approximately $2,688,941.35. This trade represents a 8.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Richard Daniell sold 17,295 shares of the company's stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $547,732.65. Following the completion of the transaction, the executive vice president owned 85,755 shares in the company, valued at approximately $2,715,860.85. This trade represents a 16.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 948,499 shares of company stock worth $30,897,071. 0.49% of the stock is owned by insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.